Skip to main content
FDA grants rare pediatric disease status to Albireo's liver disease drug
6/13/2018

Albireo Pharma's late-stage candidate A4250 was given rare pediatric disease status by the FDA. The drug is being developed as a treatment of progressive familial intrahepatic cholestasis.

Full Story: